Literature DB >> 9362427

Radiologic diagnosis of bone metastases.

D I Rosenthal1.   

Abstract

Metastatic cancer often involves the skeleton. Tumor most often reaches the bones by hematogenous spread; however, direct extension from the primary tumor or from another site of metastasis, as well as lymphatic dissemination, may occur. Clinical features depend on the affected sites and the extent of disease. The radioisotope bone scan has been the preferred imaging screening modality. Magnetic resonance imaging is probably more sensitive in the detection of axial lesions, but additional development is needed before it can replace the isotope scan in evaluation of the long bones. For patients presenting with metastatic disease, the appearance of the lesions may help to guide the search for a primary. Some helpful patterns include lytic and sclerotic lesions, "expanded" lesions, "pseudosarcomatous" lesions, acral lesions, and soft tissue ossification. Evaluation of response to therapy is problematic. Progressive sclerosis of a lytic focus generally indicates a positive response. Pitfalls in the evaluation of response include the "flare" phenomenon, which has been observed on radioisotope scans early in the course of therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9362427     DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1595::aid-cncr10>3.3.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Is 11C-choline the most appropriate tracer for prostate cancer? For.

Authors:  Ferruccio Fazio; Maria Picchio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-02       Impact factor: 9.236

Review 2.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

Review 3.  Diagnosis of non-osseous spinal metastatic disease: the role of PET/CT and PET/MRI.

Authors:  Ali Batouli; John Braun; Kamal Singh; Ali Gholamrezanezhad; Bethany U Casagranda; Abass Alavi
Journal:  J Neurooncol       Date:  2018-02-26       Impact factor: 4.130

Review 4.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

5.  Radiologic findings of adult pelvis and appendicular skeletal Langerhans cell histiocytosis in nine patients.

Authors:  You Seon Song; In Sook Lee; Jae Hyuck Yi; Kil Ho Cho; Do Kyung Kim; Jong Woon Song
Journal:  Skeletal Radiol       Date:  2010-12-29       Impact factor: 2.199

6.  Skeletal Metastasis-an Epidemiological Study.

Authors:  Balaji Zacharia; Dhiyaneswaran Subramaniam; Jerin Joy
Journal:  Indian J Surg Oncol       Date:  2017-09-28

7.  Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Authors:  Joerg Stattaus; Steffen Hahn; Thomas Gauler; Wilfried Eberhardt; Stefan P Mueller; Michael Forsting; Susanne C Ladd
Journal:  Eur Radiol       Date:  2008-08-02       Impact factor: 5.315

8.  Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis.

Authors:  Tyler J Fraum; Kathryn J Fowler; Jonathan McConathy
Journal:  Nucl Med Mol Imaging       Date:  2016-02-19

9.  Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.

Authors:  Mehmet Halit Yilmaz; Mustafa Ozguroglu; Devrim Mert; Hande Turna; Gökhan Demir; Ibrahim Adaletli; Sila Ulus; Metin Halac; Kaya Kanberoğlu
Journal:  Med Oncol       Date:  2007-11-27       Impact factor: 3.064

Review 10.  The effects of metastatic lesion on the structural determinants of bone: Current clinical and experimental approaches.

Authors:  Stacyann Bailey; David Hackney; Deepak Vashishth; Ron N Alkalay
Journal:  Bone       Date:  2019-11-21       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.